Brian R Englum1, Asvin M Ganapathi1, Matthew A Schechter1, J Kevin Harrison2, Donald D Glower1, G Chad Hughes3. 1. Department of Surgery, Duke University Medical Center, Durham, North Carolina. 2. Department of Medicine, Duke University Medical Center, Durham, North Carolina. 3. Department of Surgery, Duke University Medical Center, Durham, North Carolina. Electronic address: gchad.hughes@duke.edu.
Abstract
BACKGROUND: With initiation of transcatheter aortic valve replacement (TAVR) programs, centers may see changes in surgical aortic valve replacement (SAVR) populations and related outcomes because of more high-risk patients undergoing TAVR rather than SAVR. Little data exist on the potential changes in the risk profiles and outcomes of SAVR patients from the pre- to post-TAVR eras. As such, this study sought to evaluate changes in the SAVR population at a tertiary referral center after TAVR program initiation. METHODS: Using a single-center valve surgical database, annual volume, patient characteristics, operative details, and predicted and observed mortality for patients undergoing isolated SAVR or SAVR + coronary artery bypass grafting (CABG) from 2006 to 2013 were evaluated. Patients were divided into 3 eras: (1) pre-TAVR (January 2006-June 2009), (2) transition (July 2009-March 2011), and (3) TAVR (April 2011-June 2013). The primary analysis compared predicted and observed mortality in pre-TAVR and TAVR eras. RESULTS: From 2006 to 2013, 1,380 SAVR patients were identified, with 505 (36.6%), 330 (23.9%), and 545 (39.5%) patients from the pre-TAVR, transition, and TAVR eras, respectively. SAVR case volume increased from 131 to 256 cases per year (95.4% increase) from the pre-TAVR to the post-TAVR eras. Predicted risk of mortality (PROM) for SAVR patients from the pre-TAVR to TAVR eras by The Society of Thoracic Surgeons (STS)-PROM was stable near 3.8% (p = 0.82). Crude 30-day SAVR mortality trended down from 2.8% in the pre-TAVR era to 1.5% in the post-TAVR era (p = 0.23). CONCLUSIONS: Consistent with previous studies, initiation of a TAVR program was associated with increased SAVR volume. Risk profiles for SAVR patients in the TAVR era remained similar by the STS-PROM, indicating generally stable risk among surgical patients after launching a TAVR program. These data suggest that significant changes in the risk profiles of SAVR patients should not be expected with the initiation of a TAVR program. Further research will need to reevaluate these changes once TAVR becomes more widely available.
BACKGROUND: With initiation of transcatheter aortic valve replacement (TAVR) programs, centers may see changes in surgical aortic valve replacement (SAVR) populations and related outcomes because of more high-risk patients undergoing TAVR rather than SAVR. Little data exist on the potential changes in the risk profiles and outcomes of SAVR patients from the pre- to post-TAVR eras. As such, this study sought to evaluate changes in the SAVR population at a tertiary referral center after TAVR program initiation. METHODS: Using a single-center valve surgical database, annual volume, patient characteristics, operative details, and predicted and observed mortality for patients undergoing isolated SAVR or SAVR + coronary artery bypass grafting (CABG) from 2006 to 2013 were evaluated. Patients were divided into 3 eras: (1) pre-TAVR (January 2006-June 2009), (2) transition (July 2009-March 2011), and (3) TAVR (April 2011-June 2013). The primary analysis compared predicted and observed mortality in pre-TAVR and TAVR eras. RESULTS: From 2006 to 2013, 1,380 SAVR patients were identified, with 505 (36.6%), 330 (23.9%), and 545 (39.5%) patients from the pre-TAVR, transition, and TAVR eras, respectively. SAVR case volume increased from 131 to 256 cases per year (95.4% increase) from the pre-TAVR to the post-TAVR eras. Predicted risk of mortality (PROM) for SAVR patients from the pre-TAVR to TAVR eras by The Society of Thoracic Surgeons (STS)-PROM was stable near 3.8% (p = 0.82). Crude 30-day SAVR mortality trended down from 2.8% in the pre-TAVR era to 1.5% in the post-TAVR era (p = 0.23). CONCLUSIONS: Consistent with previous studies, initiation of a TAVR program was associated with increased SAVR volume. Risk profiles for SAVR patients in the TAVR era remained similar by the STS-PROM, indicating generally stable risk among surgical patients after launching a TAVR program. These data suggest that significant changes in the risk profiles of SAVR patients should not be expected with the initiation of a TAVR program. Further research will need to reevaluate these changes once TAVR becomes more widely available.
Authors: David S Bach; Derrick Siao; Steven E Girard; Claire Duvernoy; Benjamin D McCallister; Sarah K Gualano Journal: Circ Cardiovasc Qual Outcomes Date: 2009-10-27
Authors: David M Shahian; Sean M O'Brien; Giovanni Filardo; Victor A Ferraris; Constance K Haan; Jeffrey B Rich; Sharon-Lise T Normand; Elizabeth R DeLong; Cynthia M Shewan; Rachel S Dokholyan; Eric D Peterson; Fred H Edwards; Richard P Anderson Journal: Ann Thorac Surg Date: 2009-07 Impact factor: 4.330
Authors: S Chris Malaisrie; Eric Tuday; Brittany Lapin; Edward Wang; Richard Lee; Edwin C McGee; Charles Davidson; Patrick M McCarthy Journal: Eur J Cardiothorac Surg Date: 2011-01-12 Impact factor: 4.191
Authors: Vuyisile T Nkomo; Julius M Gardin; Thomas N Skelton; John S Gottdiener; Christopher G Scott; Maurice Enriquez-Sarano Journal: Lancet Date: 2006-09-16 Impact factor: 79.321
Authors: S W Grant; M P Devbhandari; A D Grayson; I Dimarakis; I Kadir; D M T Saravanan; R D Levy; S G Ray; B Bridgewater Journal: Heart Date: 2010-10 Impact factor: 5.994
Authors: N Piazza; A Otten; C Schultz; Y Onuma; H M Garcia-Garcia; E Boersma; P de Jaegere; P W Serruys Journal: Heart Date: 2009-09-10 Impact factor: 5.994
Authors: Sean M O'Brien; David M Shahian; Giovanni Filardo; Victor A Ferraris; Constance K Haan; Jeffrey B Rich; Sharon-Lise T Normand; Elizabeth R DeLong; Cynthia M Shewan; Rachel S Dokholyan; Eric D Peterson; Fred H Edwards; Richard P Anderson Journal: Ann Thorac Surg Date: 2009-07 Impact factor: 4.330
Authors: Ana López-de-Andrés; Napoleon Perez-Farinos; Javier de Miguel-Díez; Valentín Hernández-Barrera; Manuel Méndez-Bailón; José M de Miguel-Yanes; Rodrigo Jiménez-García Journal: Cardiovasc Diabetol Date: 2018-10-16 Impact factor: 9.951
Authors: Louise Y Sun; Anna Chu; Derrick Y Tam; Xuesong Wang; Jiming Fang; Peter C Austin; Christopher M Feindel; Garth H Oakes; Vicki Alexopoulos; Natasa Tusevljak; Maral Ouzounian; Douglas S Lee Journal: CMAJ Date: 2021-11-22 Impact factor: 8.262
Authors: Joel N Papak; Joseph C Chiovaro; North Noelck; Laura D Healy; Michele Freeman; Jacquelyn A Quin; Robin Paynter; Allison Low; Karli Kondo; Owen J T McCarty; Devan Kansagara Journal: Ann Thorac Surg Date: 2018-11-17 Impact factor: 4.330